Neuroprotective Peptide Davunetide Improved Real-World Functioning but Not Test Scores in Schizophrenia
Intranasal davunetide didn't significantly improve cognitive test scores in schizophrenia but did improve real-world functional capacity, suggesting the peptide may benefit practical abilities that tests don't capture.
Quick Facts
What This Study Found
Intranasal davunetide (NAP peptide) did not significantly improve cognitive test scores (MCCB) versus placebo in 63 people with schizophrenia over 12 weeks. However, it did significantly improve functional capacity — the ability to perform real-world tasks — as measured by the UPSA (p = 0.048).
The 5 mg dose showed stronger effects than 30 mg, with effect sizes of d = 0.74 for functional capacity and d = 0.34 for cognition. The peptide was well tolerated with no significant side effects. The authors estimated 45–50 subjects per group would be needed to detect significant cognitive effects in future trials.
Key Numbers
n=63 · 3 arms (5 mg, 30 mg, placebo) · 12 weeks · MCCB cognition: p = 0.45 (not significant) · UPSA functional capacity: p = 0.048 (significant) · effect sizes: d = 0.74 (5 mg UPSA), d = 0.48 (30 mg UPSA), d = 0.34 (5 mg MCCB) · 0 significant adverse events
How They Did This
Multicenter, double-blind, parallel-group randomized clinical trial. 63 adults with schizophrenia were assigned to intranasal davunetide at 5 mg, 30 mg, or placebo for 12 weeks while continuing their current antipsychotic medications. Cognition was assessed using the MATRICS battery (MCCB), and functional capacity using UPSA and SCoRS scales.
Why This Research Matters
Cognitive dysfunction is the biggest predictor of disability in schizophrenia, yet no approved drugs effectively treat it. Antipsychotics control hallucinations and delusions but do almost nothing for thinking problems. Davunetide's improvement of functional capacity — even without clear cognitive test score improvements — is intriguing because real-world functioning is ultimately what matters most for patients. The dissociation between test scores and functional outcomes raises important questions about how we measure cognitive benefit.
The Bigger Picture
Davunetide (NAP) is derived from activity-dependent neuroprotective protein (ADNP) and was one of the more promising neuroprotective peptides to reach clinical trials. This schizophrenia trial is notable because it found an effect on functional capacity — what patients can actually do in daily life — even when traditional cognitive tests missed it. This dissociation has influenced how the field thinks about measuring treatment benefits. Though davunetide's development stalled after a failed progressive supranuclear palsy trial, the NAP peptide concept continues to influence neuroprotective research.
What This Study Doesn't Tell Us
Small sample size (n=63 across three arms, ~21 per group) — underpowered to detect moderate cognitive effects. The primary cognitive measure (MCCB) was not significant. Only 12 weeks of treatment — longer durations might show different results. The significant UPSA finding could be a chance result given the small sample and multiple comparisons. Davunetide was later discontinued for progressive supranuclear palsy, which may have dampened enthusiasm for schizophrenia development.
Questions This Raises
- ?Why did davunetide improve functional capacity but not cognitive test scores — are the tests missing something important?
- ?Would a larger, longer trial with the 5 mg dose show significant cognitive improvements alongside functional gains?
- ?Could other neuroprotective peptides succeed where davunetide's development stalled?
Trust & Context
- Key Stat:
- d = 0.74 functional improvement A medium-to-large effect size for functional capacity improvement with the 5 mg dose — a meaningful real-world benefit even though formal cognitive test scores didn't reach significance.
- Evidence Grade:
- Moderate evidence: a well-designed, multicenter, double-blind RCT with appropriate outcome measures. However, the small sample size (n=63 across three arms) limits statistical power. The primary cognitive endpoint was negative; the significant functional finding, while encouraging, comes from a secondary measure in an underpowered study.
- Study Age:
- Published in 2012. Davunetide's clinical development was later discontinued after failing in a progressive supranuclear palsy trial (2014). The schizophrenia indication was not further pursued, but the findings remain relevant to neuroprotective peptide research.
- Original Title:
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
- Published In:
- Schizophrenia research, 136(1-3), 25-31 (2012)
- Authors:
- Javitt, Daniel C, Buchanan, Robert W, Keefe, Richard S E, Kern, Robert, McMahon, Robert P, Green, Michael F, Lieberman, Jeffrey, Goff, Donald C, Csernansky, John G, McEvoy, Joseph P, Jarskog, Fred, Seidman, Larry J, Gold, James M, Kimhy, David, Nolan, Karen S, Barch, Deanna S, Ball, M Patricia, Robinson, James, Marder, Stephen R
- Database ID:
- RPEP-01970
Evidence Hierarchy
Participants are randomly assigned to treatment or placebo groups to test cause and effect.
What do these levels mean? →Frequently Asked Questions
What is davunetide and how does it work?
Davunetide (also called NAP or AL-108) is a small peptide derived from a naturally occurring brain protein called activity-dependent neuroprotective protein (ADNP). It's believed to protect nerve cells by stabilizing microtubules — the structural scaffolding inside brain cells. It's delivered as a nasal spray, allowing it to reach the brain more directly.
Why did davunetide improve functioning but not test scores?
Cognitive tests measure specific mental abilities in artificial conditions, while functional capacity tests assess how well someone can perform real-world activities. The drug may have improved aspects of brain function — like motivation, processing speed, or integration of skills — that help with daily tasks but don't show up on standardized cognitive tests. This finding has broader implications for how the field measures treatment success.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01970APA
Javitt, Daniel C; Buchanan, Robert W; Keefe, Richard S E; Kern, Robert; McMahon, Robert P; Green, Michael F; Lieberman, Jeffrey; Goff, Donald C; Csernansky, John G; McEvoy, Joseph P; Jarskog, Fred; Seidman, Larry J; Gold, James M; Kimhy, David; Nolan, Karen S; Barch, Deanna S; Ball, M Patricia; Robinson, James; Marder, Stephen R. (2012). Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.. Schizophrenia research, 136(1-3), 25-31. https://doi.org/10.1016/j.schres.2011.11.001
MLA
Javitt, Daniel C, et al. "Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.." Schizophrenia research, 2012. https://doi.org/10.1016/j.schres.2011.11.001
RethinkPeptides
RethinkPeptides Research Database. "Effect of the neuroprotective peptide davunetide (AL-108) on..." RPEP-01970. Retrieved from https://rethinkpeptides.com/research/javitt-2012-effect-of-the-neuroprotective
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.